Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 3/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.38 |
| ▸ | P2RX3 | P56373 | 3/20 | 0.38 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.38 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.38 |
| ▸ | F12 | P00748 | 1/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.37 |
| ▸ | GRM5 | P41594 | 1/20 | 0.37 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.37 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.37 |
| ▸ | KIT | P10721 | 1/20 | 0.36 |
| ▸ | PRKCI | P41743 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24469848 | 0.89 | P2RX3 (0.42) | P2RX3F12PDE10APARP1TNKS2 | |
| SCHEMBL24484074 | 0.86 | NAMPT (0.40) | NAMPTGPR119P2RX3DDB1CRBN | |
| SCHEMBL29670401 | 0.86 | NAMPT (0.40) | NAMPTGPR119P2RX3DDB1CRBN | |
| SCHEMBL24469807 | 0.77 | P2RX3 (0.43) | P2RX3F12PARP1TNKS2PARP2 | |
| SCHEMBL22717415 | 0.71 | GPR119 (0.42) | GPR119P2RX3F12PARP1TNKS2 | |
| SCHEMBL24914388 | 0.70 | DDB1 (0.52) | DDB1CRBNF12GRM5PARP1 | |
| SCHEMBL22845220 | 0.70 | ABHD6 (0.39) | GPR119P2RX3F12PARP1TNKS2 | |
| SCHEMBL415023 | 0.69 | MTHFD2 (0.52) | NAMPTGPR119PDE10APARP1TNKS2 | |
| SCHEMBL3965888 | 0.69 | NAMPT (0.45) | NAMPTGPR119GRM5GRM1KIT | |
| SCHEMBL4400855 | 0.68 | NR1H2 (0.52) | NAMPTGPR119GRM5GRM1KIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11820773-B2 | Tricyclic compounds | ALIGOS THERAPEUTICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| US-11820773-B2 | Tricyclic compounds | ALIGOS THERAPEUTICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| US-20220169650-A1 | TRICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2022-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220169650-A1 | TRICYCLIC COMPOUNDS | SLC10A1, PKD1, CEL | NAMPT 877/4885GPR119 1165/4885P2RX3 3237/4885 |
| US-11820773-B2 | Tricyclic compounds | SLC10A1, PKD1, CEL | NAMPT 877/4885GPR119 1165/4885P2RX3 3237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.